|
Jun 30
|
Senti Bio Participates in Nasdaq Amplify Spotlight Series
|
|
Jun 24
|
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
|
|
Jun 18
|
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
|
|
Apr 10
|
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
|
|
Dec 26
|
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
|
|
Dec 22
|
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
|
|
Dec 22
|
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
|
|
Nov 6
|
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
|
|
Aug 11
|
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 11
|
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
|
|
Aug 10
|
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
|